Comparison of Clinical Characteristics Between COVID-19 and H7N9 Fatal Cases: An Observational Study

Overview

Journal Front Public Health

Specialty Public Health

Date 2022 Dec 12

PMID 36504959

Authors

Hui Jiang

Fangchao Liu

Ta-Chien Chan

Jinfeng Yin

Ruowen Huang

Li Shen

Shengjin Tu

Liang Kang

Wen Liu

Na Zhao

Di Zhang

Wangli Xu

Weimin Li

Shelan Liu

Chaolin Huang

Affiliations

Soon will be listed here.

Abstract

Objective: The outbreak of COVID-19 in 2020 is reminiscent of the H7N9 outbreak in 2013, which poses a huge threat to human health. We aim to compare clinical features and survival factors in fatal cases of COVID-19 and H7N9.

Methods: Data on confirmed COVID-19 and H7N9 fatal cases identified in mainland China were analyzed to compare demographic characteristics and clinical severity. Survival curves were estimated by the Kaplan-Meier method and compared using log-rank tests and a restricted mean survival time model. A Cox regression model was used to identify survival factors in fatal cases of COVID-19 and H7N9.

Results: Similar demographic characteristics were observed in fatal cases of COVID-19 and H7N9. The proportion of fatal cases of H7N9 receiving antibiotics, antiviral drugs, and oxygen treatment was higher than that of COVID-19. The potential protective factors for fatal COVID-19 cases were receiving antibiotics (HR: 0.37, 95% CI: 0.22-0.61), oxygen treatment (HR: 0.66, 95% CI: 0.44-0.99), and corticosteroids (HR: 0.46, 95% CI: 0.35-0.62). In contrast, antiviral drugs (HR: 0.21, 95% CI: 0.08-0.56) and corticosteroids (HR: 0.45, 95% CI: 0.29-0.69) were the protective factors for H7N9 fatal cases.

Conclusion: The proportion of males, those having one or more underlying medical condition, and older age was high in COVID-19 and H7N9 fatal cases. Offering antibiotics, oxygen treatment, and corticosteroids to COVID-19 cases extended the survival time. Continued global surveillance remains an essential component of pandemic preparedness.

References

Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

Wang X, Jiang H, Wu P, Uyeki T, Feng L, Lai S . Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013-17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017; 17(8):822-832. PMC: 5988584. DOI: 10.1016/S1473-3099(17)30323-7. View

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

Li C, Chen H . H7N9 Influenza Virus in China. Cold Spring Harb Perspect Med. 2020; 11(8). PMC: 8327827. DOI: 10.1101/cshperspect.a038349. View

Gao H, Lu H, Cao B, Du B, Shang H, Gan J . Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013; 368(24):2277-85. DOI: 10.1056/NEJMoa1305584. View

Liao Q, Ip D, Tsang T, Cao B, Jiang H, Liu F . A clinical prediction rule for diagnosing human infections with avian influenza A(H7N9) in a hospital emergency department setting. BMC Med. 2014; 12:127. PMC: 4243192. DOI: 10.1186/s12916-014-0127-0. View

Sethuraman N, Jeremiah S, Ryo A . Interpreting Diagnostic Tests for SARS-CoV-2. JAMA. 2020; 323(22):2249-2251. DOI: 10.1001/jama.2020.8259. View

Zeng X, Tian G, Shi J, Deng G, Li C, Chen H . Vaccination of poultry successfully eliminated human infection with H7N9 virus in China. Sci China Life Sci. 2018; 61(12):1465-1473. DOI: 10.1007/s11427-018-9420-1. View

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y . Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223):507-513. PMC: 7135076. DOI: 10.1016/S0140-6736(20)30211-7. View

10.

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G . Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020; 323(18):1843-1844. PMC: 7066521. DOI: 10.1001/jama.2020.3786. View

11.

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang H, Mercer S . Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020; 8(8):e1003-e1017. PMC: 7295519. DOI: 10.1016/S2214-109X(20)30264-3. View

12.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y . Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1):110-118. PMC: 7152876. DOI: 10.1016/j.jaci.2020.04.006. View

13.

Banik G, Alqahtani A, Booy R, Rashid H . Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin. 2016; 31(1):81-4. PMC: 7090713. DOI: 10.1007/s12250-015-3679-z. View

14.

Yang S, Wu J, Ding C, Cui Y, Zhou Y, Li Y . Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infect Dis. 2017; 17(7):716-725. PMC: 7164789. DOI: 10.1016/S1473-3099(17)30227-X. View

15.

Zhang T, Wang Q, Wang Y, Bai G, Dai R, Luo L . Early Surveillance and Public Health Emergency Responses Between Novel Coronavirus Disease 2019 and Avian Influenza in China: A Case-Comparison Study. Front Public Health. 2021; 9:629295. PMC: 8383042. DOI: 10.3389/fpubh.2021.629295. View

16.

Kucirka L, Lauer S, Laeyendecker O, Boon D, Lessler J . Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med. 2020; 173(4):262-267. PMC: 7240870. DOI: 10.7326/M20-1495. View

17.

Russell C, Millar J, Baillie J . Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395(10223):473-475. PMC: 7134694. DOI: 10.1016/S0140-6736(20)30317-2. View

18.

Xu X, Chen P, Wang J, Feng J, Zhou H, Li X . Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020; 63(3):457-460. PMC: 7089049. DOI: 10.1007/s11427-020-1637-5. View